- A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease (Phase Ib) – US (website)
Enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention
IRDiRC – Inserm US14
Plateforme Maladies Rares | Rare Diseases Platform
96 rue Didot
Tel: +33 1 56 53 81 37
Fax: +33 1 56 53 81 38
This site is provided on an “as available” basis. While IRDiRC believes the content on this site to be correct, IRDiRC makes no representations or warranties regarding the accuracy, completeness, currency or intellectual property rights of or relating to any content displayed.